China military Network released, the Academy of Military Sciences Academy of military Medicine Chen Wei led the scientific research team, successfully developed a recombinant new crown vaccine, and was approved on March 16 to launch a clinical trial.
From this, the new crown vaccine patent approved, is the previous Chen Wei academician team developed the adenovirus vector vaccine (Ad5-nCoV vaccine).
According to the patent summary, the invention provides a new coronavirus vaccine with human type 5 replication defect adenovirus as a carrier.
The vaccine has good immunogenicity in mouse and guinea pig models and can induce strong cellular and humoral immune responses in a short period of time.
In addition, the preparation of the vaccine is rapid and simple, and large-scale production can be realized in the short term to deal with sudden outbreaks.
Since January 31,2020, the disease caused by new coronavirus infection has been listed by the World Health Organization as a "public health emergency of international concern ". The international community and countries all over the world are encouraging the development of new coronavirus vaccines for prevention.
The guiding principles are clear. In order to speed up the development and marketing of the new crown vaccine, phase III clinical trials are allowed before determining the most appropriate immunization procedures and doses. Consideration can be given to changing immunization procedures (such as increasing doses) during phase III clinical trials or optimizing them after listing.
The protective efficacy of the new crown vaccine should be evaluated by the phase III clinical protection efficacy test. At the same time, the safety risk of vaccine products and the risk of vaccination should be evaluated.
In addition, the safety and clinical protection of the market, the safety and clinical protection effect should be observed in the case of large-scale inoculation, and the protection persistence should be studied.
Project leader
Back to the project leader —— academician Chen Wei.
CNMOULDING thanks to those who pay tribute to human health, they will always be remembered.
According to public information, Chen Wei was born in February 1966, an expert in biosafety, academician of the Chinese Academy of Engineering, director and researcher of the Institute of Bioengineering of the Academy of Military Medicine of the Chinese people's Liberation Army, professional and technical level 5, and major general rank.
She not only made a contribution to SARS but also went to Africa to fight Ebola in 2014, the prototype of Dr. Chen in Wolf Warriors 2.
January 26 this year, the second lunar year, Chen Wei led the expert group stationed in Wuhan.
Two days later, on January 28, a new coronavirus nucleic acid detection kit developed by the military Medical Research Institute and local companies was approved by the State Drug Administration to obtain a medical device registration certificate.
On January 30, the emergency tent mobile testing laboratory of the Academy of Military Sciences began to operate, and the detection time of nucleic acid was greatly shortened and the diagnosis speed was accelerated by using the self-developed detection kit and the automatic nucleic acid extraction technology.
On March 16, the recombinant new crown vaccine developed by Chen Wei academician team passed the clinical study registration review and was approved to enter the clinical trial at 20.18 on the same day.
The first 108 volunteers have been vaccinated since March 16. Subsequently, they were arranged to live in Wuhan Secret Service Center centralized isolation observation.
It is worth saying that academician Chen Wei was the first person to be vaccinated.
August 11, according to CCTV military reports, Chen Wei won the "people's hero" national honorary title. For the fight against the epidemic, she led the team to develop a recombinant new crown vaccine, in the domestic and international first into the I phase, phase II clinical trials, to verify the safety and immunogenicity of the vaccine.
没有评论:
发表评论